Overview of Bromphen

Property	Description
Active ingredients	Brompheniramine, Phenylpropanolamine
Form	Oral syrup, tablets, extended-release capsules
Pharmacological class	Antihistamine and Sympathomimetic combination
General purpose	Relief from upper respiratory symptoms and congestion
Origin	Synthetic compound-derived

Defining Bromphen: Combination Product and Core Components

Bromphen is fundamentally defined as a synthetic, fixed-dose combination product intended for oral administration, integrating two functionally distinct active substances. It is classified as an Antihistamine and Sympathomimetic combination, reflecting the dual pharmacological action required to manage cold and allergy symptoms. The specific composition includes the maleate salt of Brompheniramine and the hydrochloride salt of Phenylpropanolamine. This dual-agent structure is engineered to simultaneously address separate aspects of respiratory distress, a strategy clinically recognized for optimizing symptomatic relief. Brompheniramine is a first-generation antihistamine used to relieve symptoms of the common cold and allergies.

Pharmacological Classification and Available Forms

The two active ingredients in Bromphen belong to separate, specific pharmacological categories. Brompheniramine is classified as a first-generation antihistamine of the alkylamine class, which works by engaging in Histamine H1 antagonism. In contrast, Phenylpropanolamine is classified as a sympathomimetic amine and adrenergic decongestant that operates by inducing vasoconstriction. This particular pairing of a sedating antihistamine and a systemic decongestant is a distinctive feature of the Bromphen formulation. The combination product is available to the patient in various dosage forms, including oral syrup, liquid preparations, tablets, and extended-release capsules.

General Therapeutic Purpose

The general therapeutic purpose of Bromphen is to provide concurrent symptomatic relief from the primary manifestations of upper respiratory allergies and common cold symptoms. The Brompheniramine component aims to alleviate hypersensitivity symptoms such as persistent sneezing, watery eyes, and rhinorrhea by blocking histamine activity. Simultaneously, the Phenylpropanolamine component’s vasoconstriction action reduces tissue edema within the nasal passages, directly relieving the sensation of nasal and sinus congestion. The presence of an antihistamine and a decongestant provides effective, multi-symptom relief for patients. The overall effect is a comprehensive approach to easing the discomfort associated with congested breathing.

Regulatory References

National Library of Medicine

What side effects are possible with Bromphen?

Possible Side Effects and Safety Information

The official safety profile for the Brompheniramine/Phenylpropanolamine combination reflects the dual nature of its components, presenting effects across multiple physiological systems as documented in regulatory sources.

Documented Adverse Reactions

The documented adverse reactions primarily involve the Nervous System (e.g., drowsiness, sedation, dizziness, confusion, or restlessness) and have Anticholinergic Effects (e.g., dryness of the mouth, nose, or throat, blurred vision, and difficulty in urination). Gastrointestinal effects may include nausea, vomiting, diarrhea, constipation, or epigastric distress. Furthermore, the drug may be associated with Cardiovascular Effects such as palpitation or an increase in blood pressure.

Serious Safety Concerns

Regulatory documents highlight serious adverse reactions and safety limitations. One of the active components, Phenylpropanolamine (PPA), has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain), which prompted advisories against its consumer use by the U.S. Food and Drug Administration (FDA). Other serious reactions documented in official labeling include anaphylaxis (severe allergic reaction) and hemolytic anemia.

Population-Specific Safety Considerations and Contraindications

This medication is contraindicated for use in newborn or premature infants. Older adults may be more susceptible to adverse effects, including dizziness, confusion, and urinary issues. Official labeling also lists contraindications based on patient conditions, such as narrow-angle glaucoma, prostatic hypertrophy (difficulty urinating), severe hypertension, and concurrent treatment with Monoamine Oxidase Inhibitors (MAOIs), due to the risk of severe blood pressure elevation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Brompheniramine/Phenylpropanolamine overdose details severe clinical manifestations and mandatory emergency actions.

Overdose presents with significant effects across the Central Nervous System and cardiovascular system. Documented manifestations include rapid heartbeat (tachycardia), hypertension, dilated pupils, and severe anticholinergic signs such as flushing and difficulty urinating. Serious, life-threatening outcomes are explicitly associated with the sympathomimetic component, including the risk of hemorrhagic stroke, seizure, and severe cardiac rhythm disturbances.

Classification	Manifestation or Action
Life-Threatening Risk	Hemorrhagic stroke, severe cardiac arrhythmias
CNS Manifestations	Seizure, hallucinations, severe agitation

Immediate emergency medical attention is required at the first suspicion of an overdose. Regulatory documents state that individuals must immediately seek emergency medical attention and contact a poison control center. If the person is unconscious or experiencing difficulty breathing, local emergency services must be called. Management is supportive, as no specific antidote is known, and procedures may include administering activated charcoal, performing gastric lavage, and requiring continuous cardiac monitoring (ECG). Special consideration is noted for children, who may be susceptible to paradoxical excitation.

Therapeutic Uses of Bromphen

What Bromphen Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms associated with acute upper respiratory conditions and allergies. It is relevant when symptoms create noticeable functional strain.

Easing Symptoms of Seasonal and Perennial Allergic Rhinitis

The medication is commonly used across conditions characterized by episodic or fluctuating symptom patterns driven by allergens, such as allergic rhinitis and hay fever. It is relevant for managing symptoms that interfere with daily comfort, such as frequent sneezing, rhinorrhea (runny nose), and the itching sensation in the eyes and throat. This application provides support that helps ease the overall symptom burden and may assist patients with maintaining functional stability.

“This combination is relevant for easing symptoms and supports multi-symptom relief.”

Managing Congestion from Colds and Sinus Issues

Bromphen is relevant in conditions presenting with systemic or localized discomfort, such as nasal and sinus congestion associated with the common cold or sinusitis. The medication assists in addressing groups of symptoms that may appear suddenly, like stuffiness and pressure, and contributes to easing the overall symptom load during acute episodes. This combination is relevant across therapeutic contexts involving the common cold, allergic rhinitis, hay fever, and sinusitis.

Symptom Management Note

This medication plays a role in managing physical obstructive symptoms, like nasal stuffiness and sinus pressure, making it commonly used when short-term symptomatic assistance is needed.

Regulatory References

Philippine FDA product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bromphen?

Eligibility for Bromphen is strictly defined by official regulatory labeling, primarily due to the properties of its combination ingredients: Brompheniramine (antihistamine) and Phenylpropanolamine (sympathomimetic).

Absolute Contraindications (Must Not Use)

Population/Condition	Restriction Driver
Severe Hypertension or Coronary Artery Disease	Sympathomimetic component
Narrow-Angle Glaucoma or Urinary Retention	Anticholinergic component
Newborns and Premature Infants	Antihistamine component
MAO Inhibitor use (within 14 days)	Risk of Hypertensive Crisis

Conditional Use and Restrictions

Age and Development: Use is typically established for Adults and Adolescents (ge 12 years). The medicine is not recommended for children under six years of age. Older adults should use the medication with caution due to increased sensitivity to its effects.

Comorbidities: Caution is required for patients with conditions sensitive to sympathetic stimulation, including Diabetes Mellitus and Thyroid Disease (hyperthyroidism).

Pregnancy and Lactation: Use during pregnancy is generally discouraged unless directed by a physician, with avoidance often advised in the third trimester. Use is not recommended for individuals who are breastfeeding, as the drug passes into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Bromphen, a combination of an antihistamine and a sympathomimetic, around two primary pharmacodynamic risks: severe hypertension and central nervous system (CNS) depression.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated. This combination is prohibited due to the risk of a hazardous interaction resulting in severe hypertensive effects. A mandatory separation window of 14 days is required before starting Bromphen after discontinuing an MAOI, as specified in regulatory labels.

Pharmacodynamic and Substance Interactions

Interacting Category	Official Interaction Outcome
CNS Depressants (including opioid pain relievers, sedatives, and other antihistamines)	Additive CNS depression resulting in increased drowsiness and sedation.
Alcohol	Consumption may increase drowsiness and dizziness due to additive CNS depressant effects.
Volatile Anesthetics (e.g., Halothane)	Increased risk of ventricular arrhythmias due to enhanced myocardial sensitivity.
Other Sympathomimetics	Restriction is advised due to heightened risk of hypertension and cardiovascular effects.

Population-Specific Notes

Regulatory documents note that elderly patients may show increased susceptibility to CNS effects, such as confusion. Children may exhibit the paradoxical effect of excitement or agitation.

Mechanism of Action

The action of Bromphen (Brompheniramine/Phenylpropanolamine) is driven by the complementary modulation of two distinct biological systems: the histaminergic pathway and the sympathetic nervous system, which collectively influence inflammation and vascular tone in the upper respiratory tract.

Molecular Blockade of Histamine Receptors

This domain centers on Brompheniramine's role as a competitive antagonist of the histamine H1 receptor. By occupying these receptors, the drug suppresses the signaling cascade initiated by the release of histamine, a key inflammatory mediator. This molecular action directly modifies the early steps that shape systemic physiological outcomes, leading to a reduction in capillary permeability and subsequent fluid exudation into the nasal mucosa, and reduces H1-mediated sensory nerve excitation.

Targeted Activation of Adrenergic Vasculature

The second domain involves Phenylpropanolamine, a sympathomimetic amine that primarily targets alpha-1 (alpha1) adrenergic receptors on blood vessel walls. Through both direct agonism and the indirect release of norepinephrine, the mechanism initiates a rapid signaling sequence that triggers vasoconstriction in the nasal arteries. This physical narrowing of the vessels modulates vascular responses, resulting in a physiological consequence that reduces blood volume and tissue bulk secondary to vasoconstriction.

Dosage and Administration Information

How to Use Bromphen: Official Administration Guidelines

The official instructions for Bromphen (Brompheniramine Maleate/Phenylpropanolamine HCl) administration establish a standardized oral dosing protocol, which may differ regionally based on product approval status. The medication is designated for short-term use only.

Administration Logistics

Feature	Guideline (Strictly Label-Based)
Route of administration	Oral administration only (syrup, drops, tablet, or extended-release capsule).
Frequency	Immediate-release forms are typically taken 3 to 4 times a day or every 6 to 8 hours.
Food Relationship	May be taken with food if administration without food causes stomach upset.
Measurement	Liquid doses must be measured accurately using the supplied dose-measuring device.

Labeled Dosing Regimens

Population Group	Labeled Single Dose (Syrup/Liquid)
Adults	5 to 10 mL per dose
Children 7–12 years	5 mL per dose
Children 3–6 years	2.5 mL per dose

Special Procedural Conditions

Extended-release formulations must be swallowed whole and must not be crushed, broken, or chewed. Specific lower doses are prescribed for infants in defined age brackets, and the use is restricted in neonates and premature infants. This protocol provides the explicit framework for correct, standardized product administration.

Recent Clinical Evidence

Evidence for Use in Common Cold Symptoms

This section summarizes the design and outcomes measured in Randomized Controlled Trials (RCTs) and systematic reviews that have explored how symptoms changed during the use of the antihistamine-decongestant combination in the context of the common cold, including data on overall symptom scores and rhinorrhea (runny nose).

Research explored patterns of symptom evolution in adults, with measured changes being primarily observed during the first day or two of use. The evidence quality across various common cold interventions is frequently variable. Research highlights changes measured during the study period but does not determine whether an individual will respond similarly.

Clinical trial evidence related to how symptoms evolved in young children has been described as uncertain, with data indicating that sufficient evidence of change in some core symptoms is currently insufficient. Furthermore, long-term outcomes, such as sustained symptom management, are not fully established by the existing short-term RCTs, as most studies observe responses over defined time intervals lasting only a few days.

Evidence for Use in Allergic Rhinitis Symptoms

Clinical trials was studied for its application in conditions involving periods of heightened symptoms, such as seasonal or perennial allergic rhinitis. These studies, which included RCTs, aimed to measure changes in a Composite Nasal Symptom Score (congestion, sneezing, itching, runny nose) and scores for watery eyes in adults and adolescents.

Research describes that measured changes in nasal congestion were primarily associated with the presence of the decongestant component. Evidence quality varies across studies, and long-term effects are not fully established, as there is limited information characterizing how symptoms evolved over an entire allergy season.

⏱️ Evidence in Special Populations and Follow-up Duration

The combination was evaluated in specific population subgroups. For adults, research examined the decongestant component in small patient cohorts with controlled hypertension to monitor physiological strain. These studies focused on very short-term effects, with observations limited to acute response after a single dose or a small number of doses. Consequently, there is limited information for long-term outcomes for this combination in any population, and data for certain sensitive groups remain insufficient.

Evidence Consistency, Quality, and Uncertainty

The consistency of evidence varies, particularly when comparing trials for the common cold versus allergic rhinitis. The evidence base highlights that results apply only to the specific populations studied, such as patients with stable, controlled hypertension. Therefore, research does not characterize how symptoms or physiological measures evolved in patients with severe or uncontrolled conditions. Overall, findings describe group patterns, and evidence highlights what is known—and what is still uncertain—about the combination's use.

Frequently Asked Questions (FAQ)

Common questions about Bromphen (FAQ)

Q: Is Bromphen available over the counter?

A: Regulatory product information sometimes identifies the combination product as a Human OTC Drug (Over-the-Counter).

However, the specific regulatory status and availability can vary depending on the product’s exact formulation and the country or region.

Q: Are there different brand names for products containing Bromphen?

A: Products containing brompheniramine maleate have been marketed under various trade names throughout their history.

These brand names, such as Bromfed and Dimetapp, are noted in drug information sources.

Q: Does Bromphen contain any ingredients besides the active drug?

A: Regulatory labels require listing all components in the product. Official product information lists the inactive ingredients (such as excipients, colors, or preservatives) along with the active drug components.

This provides a complete accounting of the product's overall composition.

Q: How quickly does Bromphen usually start to work?

A: According to pharmacokinetic data, the decongestant component (phenylpropanolamine) typically reaches its highest concentration in the blood plasma about one to two hours after a dose is taken orally.

This marker indicates when the drug is most concentrated in the body's system.

Q: How long can the effects of Bromphen be expected to last?

A: The duration of the product's effects is influenced by how the body processes both active ingredients. The antihistamine component has a reported elimination half-life of about 25 hours, while the decongestant component's half-life is shorter, around 3 to 5 hours.

The experienced effects may relate to the clearance rate of the component that primarily addresses the symptom.

Q: How long does the body take to clear Bromphen?

A: For the decongestant component, pharmacokinetic data shows that up to 80% to 90% of a dose is excreted, mostly unchanged, in the urine.

This elimination process occurs generally within 24 hours.

Q: Is there any indication that Bromphen may affect driving ability?

A: Official labeling includes an explicit warning to be careful when driving a motor vehicle or operating machinery.

Official labeling states this warning is included because side effects such as drowsiness or dizziness are documented to occur.

Q: Can Bromphen cause changes in sleep patterns?

A: Official labeling states that effects such as sleeplessness (insomnia) or nervousness are reasons for discontinuing use and consulting a healthcare provider.

These are documented adverse reactions linked to the medication’s properties.

Q: Why do some people report feeling nervous or restless after taking Bromphen?

A: Nervousness, sleeplessness, and excitability are documented adverse reactions. These effects are linked to the decongestant component, which acts as an adrenergic drug that stimulates the sympathetic nervous system.

Q: Why might someone feel dry mouth after taking Bromphen?

A: Dry mouth is a documented side effect known as an anticholinergic effect.

This occurs because the antihistamine component influences specific receptors in the body, which can lead to the drying of mucus and other secretions.

Q: Are there any common side effects of Bromphen that people report online?

A: Official product information lists the most frequent adverse reactions seen in research and practice, although it does not use the term 'common.'

These documented effects generally include sedation, dizziness, and dryness of the mouth, nose, and throat.

Q: Are there known effects of Bromphen on heart rate?

A: Regulatory-cited information and adverse reaction documents indicate that both active components have been associated with potential cardiovascular effects.

These include the possibility of an increase in heart rate (palpitation) due to the stimulating properties of the decongestant.

Q: Can taking too much Bromphen cause serious issues?

A: Yes, official regulatory information states that taking more than directed, or an overdose, can potentially cause serious harm.

Severe outcomes following overdose necessitate immediate emergency medical attention.

Q: Are there warnings about using Bromphen if someone has breathing problems?

A: Official regulatory labeling identifies specific breathing problems, such as emphysema, chronic bronchitis, or asthma, as conditions where consultation with a healthcare provider is noted before use.

Q: Does Bromphen contain pseudoephedrine?

A: No. The decongestant component in this specific formulation is Phenylpropanolamine.

While both substances are chemically similar decongestants, they are distinct active ingredients listed separately in regulatory documents.

Q: Is Bromphen the same as a cough suppressant?

A: The combination of brompheniramine and phenylpropanolamine alone is not classified as a cough suppressant. However, some commercial products containing this combination are formulated with an additional active ingredient, Dextromethorphan HBr, which is an antitussive (cough suppressant).

Q: Does Bromphen have any interactions with common pain relievers?

A: Regulatory labels indicate that the product may increase the sedative effects of other drugs that cause drowsiness, including certain pain relievers.

This potential interaction may lead to heightened sedation, and regulatory labels indicate that this is a situation where caution is typically warranted.

Q: Are interactions with prescription antidepressants a concern with Bromphen?

A: Yes, official drug interaction warnings exist. Besides the strict prohibition against Monoamine Oxidase Inhibitors (MAOIs), the labeling warns that the product may increase the sedative effects of other drugs, including certain antidepressants.

Q: Are there reported interactions between Bromphen and caffeine?

A: Studies cited in drug information sources suggest that the decongestant component, phenylpropanolamine, may interact with caffeine.

It is reported that taking this component concurrently with caffeine may significantly increase the levels of caffeine measured in the body.

Q: What does the official documentation say about using Bromphen before a medical procedure?

A: The labeling includes a specific warning about a risk of serious side effects if the product is used with certain volatile anesthetics.

This is due to the potential for the combination to increase the risk of heart rhythm problems (ventricular arrhythmias) during the procedure.

Q: Is the mechanism of action of Bromphen considered complex?

A: Regulatory documents describe the product's action through specific pharmacological terms, noting a dual mechanism.

This involves the antihistamine component blocking receptors and the decongestant component stimulating the sympathetic nervous system.

Q: Do researchers know why Bromphen affects some people differently than others?

A: While official labeling does not give explicit reasons for variation, it is recognized that differences exist in how individuals process drugs.

Factors such as individual drug metabolism and unique physiological responses to the sympathetic nervous system stimulation are known to affect outcomes.

How should Bromphen be stored and disposed of?

Bromphen must be stored under specific conditions to maintain its stability, as required by regulatory labeling.

Official Storage Requirements

Condition	Regulatory Specification
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F), with permitted short excursions to 30 C.
Protection	Store away from excess heat and moisture (not in the bathroom). Protect from light.
Container	Keep in the original container, which must be tightly closed and light-resistant.
Handling	Liquid forms of the medication must not be frozen.
Child Safety	Mandatory instruction to keep the product out of the sight and reach of children and pets.

Official Disposal Instructions

Unused or expired Bromphen should be discarded using a DEA-authorized drug take-back program or prepaid mail-back envelope. If those options are unavailable, the FDA recommends mixing the medicine with an undesirable substance (like dirt or used coffee grounds), placing the mixture in a sealed container, and discarding it in the household trash.

Bromphen